SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
WESTMINSTER, Colo., March 20, 2017 -- Surefire Medical, Inc., the developer of site-specific delivery devices for the Interventional Oncology market, announced today that the company has received regulatory approval in Mexico for its Surefire Infusion Systems and Surefire Guiding Catheters used in radioembolization and chemoembolization procedures.
“We developed our devices to enable physicians to treat patients with liver cancer in a highly targeted fashion by delivering the dose to the tumor while sparing healthy tissue,” said James E. Chomas, CEO and President of Surefire Medical. “We are excited to offer our products to the Mexican market and provide innovative delivery technology for various procedures – whether it is first-line treatment, palliative care or bridge to liver transplant.”
Having secured this regulatory approval from Mexico, the company will now market the Surefire Precision 021, Surefire Infusion System mT/LT, and Surefire Guiding Catheters, which are available in three shapes including Axis, SIM1 and Cobra.
Fewer than 20 percent of the 2.2 million worldwide cases of primary or secondary liver cancers are operable. Many can, however, be treated with chemoembolization or radioembolization, minimally invasive direct-to-target procedures.
About Surefire Medical
Surefire Medical, Inc. develops, manufactures and markets targeted delivery devices for the Interventional Oncology markets. Surefire’s core technology consists of a microcatheter with a unique expandable tip that improves tumor uptake while protecting healthy tissue. It enables physicians to target tumors with superior accuracy, control and protection. Learn more: www.surefiremedical.com.
Media contact: Jenna Clark Surefire Medical (303) 717-2339 [email protected]
